Cathy Klema

CIK 1181157 · last filed 2026-06-10

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.52M

Companies

Total Filings

Lifetime Open-Market Net

-$2.48M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

WPI price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers

PHARMACEUTICAL PRODUCT DEVELOPMENT INC — 20 joint filings, latest 2011-01-04

Actavis plc — 11 joint filings, latest 2019-05-02

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
OPRX	Director	56,137	$9.07	$509.2K	$0	5	2026-06-10
Allergan plc (AGN) Delisted	Director	25,081	—	—	$0	7	2019-05-02
ACT	Director	21,027	$48.29	$1.02M	$0	2	2015-06-08
Actavis, Inc. (WPI) Delisted	Director	44,432	—	—	-$1.70M	7	2012-08-01
PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted	Director	16,199	—	—	-$774.3K	12	2011-01-04

Recent Filings · Page 2 of 4

36 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2016-05-09	Allergan plc (AGN) Delisted	Grant (A)	+1,188	$249.9K	EDGAR
2015-06-30	Allergan plc (AGN) Delisted	Mixed	+277	$83.1K	EDGAR
2015-06-08	ACT	Mixed	+277	$83.1K	EDGAR
2013-10-03	—	Grant (A)	+19,608	$0
2013-10-02	ACT	Disp (D)	−19,608	$0	EDGAR
2013-08-14	—	Mixed	−10,001	-$221.8K
2013-05-14	—	Grant (A)	+1,877	$0
2012-08-01	Actavis, Inc. (WPI) Delisted	Mixed	—	-$888.7K	EDGAR
2012-05-14	Actavis, Inc. (WPI) Delisted	Grant (A)	+2,887	$0	EDGAR
2011-05-17	Actavis, Inc. (WPI) Delisted	Grant (A)	+3,177	$0	EDGAR

Showing 11–20 of 36

Prev Page 2 of 4 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.